You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Cubist announces exclusive option to buy Adynxx

Cubist Pharmaceuticals Inc., a Lexington company best known for its flagship drug, the antibiotic Cubicin, said Monday that it has an exclusive option to acquire Adynxx, a San Francisco company testing a pain-management drug.

Adynxx’s lead product candidate is currently designated as AYX1, and it seeks to reduce pain following surgery, Cubist said in a press release.

Continue reading below

“This option agreement with Adynxx is an example of our disciplined efforts to expand our acute care pipeline, consistent with our Building Blocks of Growth goals,” said Steven Gilman, executive vice president and chief scientific officer of Cubist, said in a statement. “We are impressed with the pre-clinical and Phase 1 results to date of AYX1 and believe this program has the potential to become an important, new therapy that may help patients to address the significant issue of post-surgical and chronic pain.”

(Building Blocks of Growth is the name that Cubist has given to what it calls its “five-year road map.”)

Cubist said it will pay Adynxx to secure the option right. Cubist will fund the consideration with cash on hand. If Cubist exercises its right to acquire Adynxx, Cubist will make additional payments to the Adynxx stockholders.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.